# Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

> **NCT01239758** · PHASE2 · TERMINATED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 11 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** ACE-031 (Extension of cohort 1 from core study, A031-03)
- **BIOLOGICAL:** ACE-031 (Extension of cohort 2 from core study, A031-03)
- **BIOLOGICAL:** ACE-031 (Extension of cohort 3 from core study, A031-03)

## Key facts

- **NCT ID:** NCT01239758
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** This study was terminated based on preliminary safety data.
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239758, "Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01239758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*